While small-molecule drugs provide essential support to the mitochondria, they do not address the genetic root of Friedreich’s Ataxia. In 2026, the Friedreich’s Ataxia Drug Market is witnessing a high-stakes pivot toward Adeno-Associated Virus (AAV) gene therapies designed to deliver functional FXN genes directly to the most affected tissues: the heart and the central nervous system...
Russian 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Tiếng Việt